Literature DB >> 11311327

Peripheral nerve exposure to HIV viral envelope protein gp120 induces neuropathic pain and spinal gliosis.

U Herzberg1, J Sagen.   

Abstract

Painful sensory neuropathy is a common and debilitating consequence of human immunodeficiency virus (HIV). The underlying causes of neuropathic pain are most likely not due to direct infection of the nervous system by active virus. The goal of this study was to determine whether epineural exposure to the HIV-1 envelope protein gp120 could lead to chronic painful peripheral neuropathy. Two doses of gp120 or BSA control were transiently delivered epineurally via oxidized cellulose wrapped around the rat sciatic nerve. Animals were assessed for neuropathic pain behaviors at several intervals from 1-30 days following nerve surgery. Allodynia and hyperalgesia were observed within 1-3 days following gp120 and sustained throughout the testing period. The gp120-exposed sciatic nerve exhibited early but transient pathology, notably axonal swelling and increased tumor necrosis factor alpha (TNF-alpha) within the nerve trunk. In contrast, intense astrocytic and microglial activation was observed in the spinal cord, and this gliosis persisted for at least 30 days following epineural gp120, in parallel with neuropathic pain behaviors. These findings demonstrate that limited peripheral nerve exposure to HIV protein can induce persistent painful sensory neuropathy that may be sustained and magnified by long-term spinal neuropathology.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311327     DOI: 10.1016/s0165-5728(01)00288-0

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  55 in total

Review 1.  Chemokines: integrators of pain and inflammation.

Authors:  Fletcher A White; Sonia K Bhangoo; Richard J Miller
Journal:  Nat Rev Drug Discov       Date:  2005-10       Impact factor: 84.694

Review 2.  "Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids.

Authors:  Linda R Watkins; Mark R Hutchinson; Erin D Milligan; Steven F Maier
Journal:  Brain Res Rev       Date:  2007-07-13

Review 3.  HIV-associated neuropathic pain: epidemiology, pathophysiology and management.

Authors:  Susama Verma; Lydia Estanislao; David Simpson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Critical role of microglial CD40 in the maintenance of mechanical hypersensitivity in a murine model of neuropathic pain.

Authors:  Ling Cao; Christopher D Palmer; Jennifer T Malon; Joyce A De Leo
Journal:  Eur J Immunol       Date:  2009-12       Impact factor: 5.532

Review 5.  Neuromuscular complications in HIV.

Authors:  Susama Verma; Elena Micsa; Lydia Estanislao; David Simpson
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

6.  HIV-gp120 and physical dependence to buprenorphine.

Authors:  J Palma; M E Abood; K Benamar
Journal:  Drug Alcohol Depend       Date:  2015-02-26       Impact factor: 4.492

7.  Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.

Authors:  Farinaz Nasirinezhad; Stanislava Jergova; James P Pearson; Jacqueline Sagen
Journal:  Neuropharmacology       Date:  2014-12-05       Impact factor: 5.250

8.  Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats.

Authors:  Erin D Milligan; Carin Twining; Marucia Chacur; Joseph Biedenkapp; Kevin O'Connor; Stephen Poole; Kevin Tracey; David Martin; Steven F Maier; Linda R Watkins
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

9.  Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy.

Authors:  Victoria C J Wallace; Julie Blackbeard; Timothy Pheby; Andrew R Segerdahl; Meirion Davies; Fauzia Hasnie; Susan Hall; Stephen B McMahon; Andrew S C Rice
Journal:  Pain       Date:  2007-04-12       Impact factor: 6.961

10.  Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy.

Authors:  Sonia K Bhangoo; Matthew S Ripsch; David J Buchanan; Richard J Miller; Fletcher A White
Journal:  Mol Pain       Date:  2009-08-12       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.